N/A N=267 WP01 - Normothermic Liver Preservation
Liver Transplantation
Primary: Percentage of Participants With Early Allograft Dysfunction (EAD) — 20.6; 23.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=52 Dupilumab Skin Barrier Function Study in Atopic Dermatitis
Atopic Dermatitis
Primary: Percent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16 — -54.6 percent change…
Phase 4 N=62 Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Influenza, Human · Transplantation Infection
Primary: Number of Patients With Local Site Reactions — 2; 2 Participants
N/A N=71 At Home Spirometry and Video Module Education for COPD Patients
COPD
Primary: Virtual Education Module Adherence — 17 Participants
N/A N=1,979 Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health
Emergencies · Aging
Primary: Number of Participants Returning to the ED Within 30 Days of the Original ED Visit — 84; 69; 51; 113 Participants
Phase 2 N=49 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
Pancreatic Cancer
Primary: Progression-free Survival — 9.2; 8.9 months
N/A N=1,113 Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
HIV Infections
Primary: PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs — 55.1; 43.50; 45.8; NA mg*hour/L — p=0.055
Phase 2 N=22 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Ewing's Sarcoma
Primary: Number of Participants With Adverse Events Determined by Laboratory Assessments and Physical Examinations — 5; 6; 9 Participants
Phase 2 N=10 Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Severe Combined Immunodeficiency Due to ADA Deficiency
Primary: Percentage of Participants With Treatment Efficacy After Treatment With OTL 101 (6 Months) — 100; 100; 90 percentage of participants
Phase 2 N=317 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Total Mayo Score at Week 8 (Induction Period) — 7.88; 5.85; 4.00; 3.27 Units on a scale — p=0.0017
Phase 2 N=328 A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
Endometriosis
Primary: Percentage of Subjects With 30% or Greater Reduction From Baseline to Week 12 in Mean Overall Pelvic Pain Score (0-3 VRS) — 34.5; 49.4; 61.5; 56.4 percentage of subjects
N/A N=22 The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Type 2 Diabetes
Primary: Change in Reactive Oxygen Species (ROS) Generation by MNC, Protein and mRNA Expression of p47phox Subunit of NADPH Oxidase, in MNC's of Obese Type 2 Diabetic Patients…
N/A N=932 Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis
Surgical Site Infection
Primary: Number of Patients With Surgical Site Infection — 29; 33 Participants — p=0.38
Phase 3 N=303 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 73.6; 0 percentage of subjects
Phase 4 N=97 Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients
Renal Transplant
Primary: Proportion of Patients Reaching Target Tacrolimus Levels (8-10 ng/mL) on Day 3 After Kidney Transplantation — 0.2; 0.14 proportion of participants — p=0.58